AstraZeneca PLC (AZN.L)
| Previous close | 12,392.00 |
| Open | 12,468.00 |
| Bid | 12,304.00 x 0 |
| Ask | 12,600.00 x 0 |
| Day's range | 12,434.00 - 12,556.68 |
| 52-week range | 9,461.00 - 12,704.00 |
| Volume | |
| Avg. volume | 2,179,508 |
| Market cap | 193.938B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 39.34 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.28 (1.82%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- Business Wire
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
WILMINGTON, Del., June 12, 2024--AstraZeneca’s FARXIGA® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older.1 The FDA approval was based on positive results from the pediatric T2NOW Phase III trial.2 FARXIGA was previously approved in the US in adults with T2D as an adjunct to diet and exercise to improve glycemic control.1
- Business Wire
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
WILMINGTON, Del., June 10, 2024--AstraZeneca’s supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT). If approved, TAGRISSO will be indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 (L858R) mutations.
- PR Newswire
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.
